Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Spatial Surgery
Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation. This 510(k)-pending technology called the TESSA ◊ Spatial Surgery System (Tracking Enabled Spatial Surgery Assistant) plans to combine personalized operative planning with a real-time, tracking enabled device using advanced imaging and augmented reality guidance to assist a surgeon in decision making. Learn more at www.spatialsurgery.com
CARTIHEAL ◊ AGILI-C ◊ Cartilage Repair Implant
Smith+Nephew's CARTIHEAL AGILI-C Cartilage Repair Implant is an FDA approved device that was previously granted breakthrough designation and is now evolving the cartilage repair landscape. The unique properties of the implant enable physicians to surgically treat patients that previously had no access to cartilage repair procedures. 1-3 In a large randomized controlled trial, when compared to the surgical standard of care, * the CARTIHEAL AGILI-C implant demonstrated:
Proven clinical superiority: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee function, pain relief, and mobility improvements over a 4-year period. 1,4 **
Significantly lower risk of TKA or osteotomy: Patients' risk of additional knee reconstruction/realignment surgery at 4 years. 4
Different patient profiles – same great results: The scaffold treats a broad group of patients across age, lesion size, and presence of osteoarthritis while delivering clinically meaningful results. 1,4, **
The use of the CARTIHEAL AGILI-C Implant in the presence of osteoarthritis will be featured during OrthoDome at AAOS on Wednesday, March 12, from 11:16-11:31 am PST. You can learn more by visiting the CARTIHEAL AGILI-C webpage here.
REGENETEN ◊ Bioinductive Implant
The REGENETEN Bioinductive Implant is a scaffold made from highly purified type I collagen fibers and has changed the way surgeons treat tendon injuries for more than ten years. 5-8 Clinical studies in rotator cuff repair have demonstrated results that surpass the current standard of care:
3x reduction in the risk of re-tear in a randomized controlled trial versus standard repair alone augmenting repair of medium-to-large full-thickness tears (at 1-year). 9***
Accelerated recovery and return to activity when used as an isolated treatment (compared with takedown and suture anchor repair), 10,11 while leading to consistent tendon healing for partial-thickness tears. 9,12
Well established technique used in >150,000 patients, with a proprietary delivery and fixation system resulting in a 15-minute procedure. 9
In addition to continued value in rotator cuff repair, usage of the REGENETEN Implant continues to increase in tendons around the body, including those in the hip, knee, and foot & ankle, where surgeons recognize its potential to improve tendon healing. You can learn more by visiting the REGENETEN webpage here.
To learn more about Smith+Nephew's Sports Medicine joint repair solutions and enabling technologies, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego March 11-13, 2025, or visit www.smith-nephew.com.
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
* Debridement or microfracture
** Over a 2- and 4-year follow-up
*** Re-tear: 8.3% vs 25.8%; Relative risk=0.32 [95% Confidence Interval 0.13-
0.83]; p=0.0106.
References
Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967
Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598
Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81
Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126
Bokor DJ, et al. Muscles Ligaments Tendons J. 2016;6(1):16-25.
Warren JR, et al. J Shoulder Elbow Surg. 2024;33(11):2515-2529
Bokor DJ, et al. Muscles Ligaments Tendons J. 2015;5(3):144-150.
Smith+Nephew 2020 REGENETEN Collagen Implant Physical Characteristics. Internal Report Internal Report. 15009769
Ruiz Ibán MÁ, et al. Arthroscopy. 2024;40(6):1760-1773.
Camacho Chacón JA, et al. J Shoulder Elbow Surg. 2024;33(9):1894-1904.
Bushnell BD, et al. Orthop J Sports Med. 2021;9(8):23259671211027850.
Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
Brookfield Wealth Solutions Announces Results for Election of Directors
BROOKFIELD, NEWS, June 10, 2025 (GLOBE NEWSWIRE) -- Brookfield Wealth Solutions (NYSE, TSX: BNT) today announced the approval of all items of business at the company's annual general and special meeting of shareholders. The meeting was held earlier today in a virtual meeting format. All five nominees proposed for election to the board of directors by holders of class A exchangeable limited voting shares ('class A shares') and all five nominees proposed for election to the board of directors by the holder of class B limited voting shares ('class B shares') were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of class A shares in regard to the election of the five directors nominated for election by this shareholder class: Director Nominee Votes For % Votes Withheld % Dr. Soonyoung Chang 23,747,124 99.17 199,324 0.83 William Cox 22,970,300 95.92 976,149 4.08 Michele Coleman Mayes 23,696,733 98.96 249,716 1.04 Lars Rodert 23,273,435 97.19 673,014 2.81 Anne Schaumburg 23,678,628 98.88 267,820 1.12 Management received a proxy from the holder of class B shares to vote all 24,000 class B shares for each of the five directors nominated for election by this shareholder class, being Barry Blattman, Gregory Morrison, Lori Pearson, Sachin Shah and Jay Wintrob. All other matters put forth at the meeting were approved by shareholder vote and a summary of all votes cast by shareholders represented at the company's annual general and special meeting of shareholders will be available electronically on EDGAR on the United States Securities and Exchange Commission's website at or on Brookfield Wealth Solutions' SEDAR profile at About Brookfield Wealth Solutions Brookfield Wealth Solutions Ltd. (NYSE, TSX: BNT) is focused on securing the financial futures of individuals and institutions through a range of retirement services, wealth protection products and tailored capital solutions. Each class A exchangeable limited voting share of Brookfield Wealth Solutions is exchangeable on a one-for-one basis with a class A limited voting share of Brookfield Corporation (NYSE, TSX: BN).
National Post
6 hours ago
- National Post
Sherritt Reports Shareholder Meeting Results, Board Appointments and Committee Updates
Article content TORONTO — Sherritt International Corporation ('Sherritt' or the 'Corporation') (TSX:S) today announced the voting results of its 2025 Annual and Special Meeting of Shareholders held June 10, 2025, the appointment of John Ewing to the Board of Directors (the 'Board'), the appointments of Leon Binedell as Executive Chairman and Shelley Brown as Lead Independent Director, respectively, and other governance updates. Article content Article content 2025 Annual and Special Meeting of Shareholders Voting Results Article content A total of 283,623,833 common shares or 57.15% of Sherritt's issued and outstanding common shares were represented in person or by proxy at the meeting. A majority of the votes were cast in favour of all items of business put forth at the meeting, including the re-appointment of Deloitte LLP as external auditors, amendments to the Corporation's stock option plan and the non-binding advisory resolution known as 'Say on Pay.' Article content Election of Directors Article content Each of the six director nominees standing for election was elected as a director of Sherritt to serve until the next annual general meeting of the company or until his or her successor is elected or appointed: Article content The full Report of Voting Results has been filed on SEDAR+ at Article content Director Appointment and Continued Commitment to Board Renewal Article content To fill the vacancy on the Board resulting from Sir Richard Lapthorne's retirement as announced on June 9, 2025, and consistent with the Corporation's ongoing commitment to good governance and Board renewal, following the meeting, the Board appointed John Ewing, bringing the total number of directors to seven. A biography for Mr. Ewing is provided below. Article content The Board intends to continue the Board renewal process with the appointment of at least one additional independent director, preferably with mining engineering expertise and the potential to assume a leadership position on the Board, by December 31, 2025. Article content All directors are independent within the meaning of applicable securities laws, other than Leon Binedell who also serves as President and CEO of the Corporation. John Ewing is the nominee of Sherritt shareholder Ewing Morris & Co. Investment Partners Ltd. ('Ewing Morris'), and Richard Moat is the nominee of Sherritt shareholder Kyma Capital Limited. Article content Board Leadership and Committee Updates Article content In connection with the reconstitution of the Board, the Corporation announces that Leon Binedell has been appointed Executive Chairman, following the retirement of former Chairman Sir Richard Lapthorne. Shelley Brown, an independent director of Sherritt since August 2024, has been named Lead Independent Director. Article content The Board committees have also been reconstituted to better align with the expertise of the new directors, including the appointment of Mr. Ewing to the Reserves, Operations and Capital Committee and Mr. Moat to the Audit Committee. Article content Additionally, the former HR Committee and the former Nominating and Corporate Governance Committee have been consolidated into a single committee. This streamlining reflects the Corporation's commitment to enhancing Board efficiency, while reducing management's administrative burden to support a greater focus on operational priorities. Article content Sherritt shareholders SC2 Inc. ('SC2') and Ewing Morris have expressed their alignment with the Corporation's ongoing Board renewal process and have committed to supporting Sherritt's director nominees through the 2026 annual meeting of shareholders. Article content 'I believe in Sherritt's potential,' said John Ewing, Sherritt Director and Co-Founder of Ewing Morris. 'I look forward to collaborating with my colleagues on the Board to help Sherritt achieve new milestones and deliver long-term value for all stakeholders.' Article content 'We are encouraged with the progress in Sherritt's Board renewal process,' said Casey McKenzie, President, SC2. 'We recognize the Corporation's potential and look forward to supporting management in driving continued improvements in performance.' Article content Leon Binedell, Sherritt Executive Chairman added: 'On behalf of Sherritt, I would like to thank Ewing Morris, SC2, and our broader shareholder base for their engagement and ongoing support. In addition, Sherritt and Seablinc look forward to re-establishing a normal commercial relationship. Over the past few years, we have worked with determination to position Sherritt for sustainable growth and value creation. I am confident that John will make valuable contributions to the Board and the Corporation as we continue to strengthen and build upon this foundation.' Article content About John Ewing Article content Mr. Ewing is Chief Investment Officer of Ewing Morris & Co. Investment Partners. He co-founded the firm in June 2011 with Darcy Morris. Mr. Ewing graduated with distinction from the University of Guelph with an Honours Bachelor of Science in Engineering degree and a Minor in Business Administration. Article content About Sherritt Article content Sherritt is a world leader in using hydrometallurgical processes to mine and refine nickel and cobalt – metals deemed critical for the energy transition. Sherritt's Moa Joint Venture has an estimated mine life of approximately 25 years and is advancing an expansion program focused on increasing annual MSP production by 20% of contained nickel and cobalt. The Corporation's Power division, through its ownership in Energas, is the largest independent energy producer in Cuba with installed electrical generating capacity of 506 MW, representing approximately 10% of the national electrical generating capacity in Cuba. The Energas facilities are comprised of two combined cycle plants that produce low-cost electricity from one of the lowest carbon emitting sources of power in Cuba. Sherritt's common shares are listed on the Toronto Stock Exchange under the symbol 'S'. Article content FORWARD-LOOKING STATEMENTS Article content Certain statements and other information included in this press release constitute 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking statements') under applicable securities laws (such statements are often accompanied by words such as 'anticipate', 'forecast', 'expect', 'believe', 'may', 'will', 'should', 'estimate', 'intend' or other similar words). All statements in this press release, other than those relating to historical information, are forward-looking statements, including, but not limited statements regarding strategies, plans and estimated production amounts resulting from expansion of mining operations at the Moa Joint Venture. The Corporation cautions readers of this press release not to place undue reliance on any forward-looking statement as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed in the forward-looking statements. The key risks and uncertainties should be considered in conjunction with the risk factors described in the Corporation's other documents filed with the Canadian securities authorities, including without limitation the 'Managing Risk' section of the Management's Discussion and Analysis for the three months ended March 31, 2025 and the Annual Information Form of the Corporation dated March 24, 2025 for the period ending December 31, 2024, which is available on SEDAR+ at Article content The forward-looking information and statements contained in this press release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any oral or written forward-looking information or statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement. Article content Article content Article content
Globe and Mail
10 hours ago
- Globe and Mail
Brookfield Business Corporation Announces Results of Annual Meeting of Shareholders
BROOKFIELD, NEWS, June 10, 2025 (GLOBE NEWSWIRE) -- Brookfield Business Corporation (the 'Corporation') (NYSE, TSX: BBUC) today announced that all ten nominees proposed for election to the board of directors of the Corporation by holders of class A exchangeable subordinate voting shares ('Exchangeable Shares') and holders of class B multiple voting shares ('Class B Shares') were elected at the Corporation's annual general meeting of shareholders held on June 10, 2025 in a virtual meeting format. Detailed results of the vote for the election of directors are set out below. In accordance with the Corporation's articles, each Exchangeable Share was entitled to one vote per share, representing a 25% voting interest in the Corporation in the aggregate, and the Class B Shares were entitled to a total of 215,082,201 votes in the aggregate, representing a 75% voting interest in the Corporation. The following is a summary of the votes cast by holders of Exchangeable Shares and Class B Shares, voting together as a single class, in regard to the election of the ten directors: Director Nominee Votes For % Votes Withheld % Cyrus Madon 279,593,990 99.90 268,437 0.10 Jeffrey Blidner 277,344,556 99.10 2,517,871 0.90 David Court 279,649,745 99.92 212,682 0.08 Stephen Girsky 279,463,948 99.86 398,479 0.14 David Hamill 279,646,581 99.92 215,846 0.08 Anne Ruth Herkes 279,648,255 99.92 214,172 0.08 John Lacey 272,069,850 97.22 7,792,577 2.78 Don Mackenzie 279,782,671 99.97 79,756 0.03 Michael Warren 279,782,332 99.97 80,095 0.03 Patricia Zuccotti 279,751,664 99.96 110,763 0.04 A summary of all votes cast by holders of the Exchangeable Shares and Class B Shares represented at the Corporation's annual meeting of shareholders is available on SEDAR+ at Brookfield Business Partners is a global business services and industrials company focused on owning and operating high-quality businesses that provide essential products and services and benefit from a strong competitive position. Investors have flexibility to invest in our company either through Brookfield Business Partners L.P. (NYSE: BBU; TSX: a limited partnership, or Brookfield Business Corporation (NYSE, TSX: BBUC). For more information, please visit Brookfield Business Partners is the flagship listed vehicle of Brookfield Asset Management's Private Equity Group. Brookfield Asset Management is a leading global alternative asset manager with over $1 trillion of assets under management. For more information, please contact:
